OSE Immunotherapeutics SA

ENXTPA:OSE Stock Report

Market Cap: €191.2m

OSE Immunotherapeutics Valuation

Is OSE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OSE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OSE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OSE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OSE?

Key metric: As OSE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OSE. This is calculated by dividing OSE's market cap by their current earnings.
What is OSE's PE Ratio?
PE Ratio4.2x
Earnings€46.03m
Market Cap€191.21m

Price to Earnings Ratio vs Peers

How does OSE's PE Ratio compare to its peers?

The above table shows the PE ratio for OSE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.9x
GNFT Genfit
9.3x41.2%€207.0m
ALERS Eurobio Scientific Société anonyme
38.9x29.0%€258.1m
ALGEN genOway Société anonyme
26.8xn/a€33.6m
ALECR Eurofins-Cerep
12.7xn/a€97.3m
OSE OSE Immunotherapeutics
4.2x-72.5%€191.2m

Price-To-Earnings vs Peers: OSE is good value based on its Price-To-Earnings Ratio (4.2x) compared to the peer average (21.9x).

Price to Earnings Ratio vs Industry

How does OSE's PE Ratio compare vs other companies in the European Biotechs Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.26.8x4.9%
OSE OSE Immunotherapeutics
 4.2x-72.5%US$201.30m
OSE 4.2xIndustry Avg. 26.8xNo. of Companies5PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
Industry Avg.26.8x4.9%
OSE OSE Immunotherapeutics
 4.2x-72.5%US$201.30m
No more companies

Price-To-Earnings vs Industry: OSE is good value based on its Price-To-Earnings Ratio (4.2x) compared to the European Biotechs industry average (26.8x).

Price to Earnings Ratio vs Fair Ratio

What is OSE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OSE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.2x
Fair PE Ratio4x

Price-To-Earnings vs Fair Ratio: OSE is expensive based on its Price-To-Earnings Ratio (4.2x) compared to the estimated Fair Price-To-Earnings Ratio (4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OSE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.79
€12.64
+43.8%
10.9%€14.12€10.80n/a3
Nov ’25€10.24
€12.60
+23.0%
10.6%€14.00€10.80n/a3
Oct ’25€7.95
€12.60
+58.5%
10.6%€14.00€10.80n/a3
Sep ’25€7.94
€11.43
+44.0%
25.8%€14.00€7.30n/a3
Aug ’25€7.80
€11.43
+46.6%
25.8%€14.00€7.30n/a3
Jul ’25€6.14
€7.15
+16.4%
2.1%€7.30€7.00n/a2
Jun ’25€8.24
€7.15
-13.2%
2.1%€7.30€7.00n/a2
May ’25€5.64
€7.15
+26.8%
2.1%€7.30€7.00n/a2
Apr ’25€4.86
€7.15
+47.1%
2.1%€7.30€7.00n/a2
Mar ’25€5.00
€7.15
+43.0%
2.1%€7.30€7.00n/a2
Feb ’25€3.81
€7.15
+87.9%
2.1%€7.30€7.00n/a2
Jan ’25€4.28
€7.15
+67.1%
2.1%€7.30€7.00n/a2
Dec ’24€3.91
€7.15
+82.9%
2.1%€7.30€7.00n/a2
Nov ’24€4.29
€7.15
+66.7%
2.1%€7.30€7.00€10.242
Oct ’24€4.26
€7.15
+67.8%
2.1%€7.30€7.00€7.952
Sep ’24€3.25
€10.80
+232.3%
40.9%€17.00€7.00€7.943
Aug ’24€3.02
€10.80
+258.2%
40.9%€17.00€7.00€7.803
Jul ’24€3.30
€10.80
+227.3%
40.9%€17.00€7.00€6.143
Jun ’24€3.69
€11.13
+201.7%
37.3%€17.00€8.00€8.243
May ’24€4.05
€13.00
+221.0%
30.8%€17.00€9.00€5.642
Apr ’24€5.09
€14.50
+184.9%
17.2%€17.00€12.00€4.862
Mar ’24€5.96
€14.50
+143.5%
17.2%€17.00€12.00€5.002
Feb ’24€6.03
€15.03
+149.5%
14.5%€17.00€12.00€3.813
Jan ’24€6.68
€15.03
+125.2%
14.5%€17.00€12.00€4.283
Dec ’23€7.26
€16.55
+128.1%
2.7%€17.00€16.10€3.912
Nov ’23€7.14
€16.55
+131.8%
2.7%€17.00€16.10€4.292

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Sanofi

€114.5b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€91.47

7D

-4.4%

1Y

7.1%

Eurofins Scientific

€8.6b

Provides various analytical testing and laboratory services worldwide.

ERF

€45.57

7D

-1.3%

1Y

-11.3%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

1.2%

1Y

-58.0%